Veliparib Trial Fails to Improve Outcomes in Ovarian Cancer

(January 26, 2015) Use of the PARP inhibitor veliparib in combination with oral cyclophosphamide did not result in an improvement in response rate or median progression-free survival compared with treatment with cyclophosphamide alone, according to a phase II study evaluating patients with high-grade serous ovarian cancer, peritoneal, fallopian tube, and BRCA-mutant ovarian cancers. The research was reported in Clinical Cancer Research.

However, the study did demonstrate that oral cyclophosphamide was well-tolerated among this patient population and was associated with responses and prolonged disease stabilization.

Read a short article about this research here;  read the scientific abstract here.

Posted on in Research

Share this page